PASG Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
8.3M
-6.8%
8.9M
-35.9%
13.8M
+60.0%
8.7M
-16.2%
10.3M
R&D
3.3M
-18.3%
4.1M
-24.5%
5.4M
+25.8%
4.3M
-25.9%
5.8M
SG&A
6.9M
+43.6%
4.8M
-2.7%
4.9M
+13.2%
4.3M
-3.8%
4.5M
Operating Income
-8272000
+6.8%
-8880000
+35.9%
-13848000
-60.0%
-8655000
+16.2%
-10334000
EBITDA
-10191000
-16.5%
-8751000
+13.9%
-10163000
-19.9%
-8474000
+16.6%
-10165000
Net Income
-7821000
-3.5%
-7559000
+41.8%
-12983000
-67.5%
-7749000
+17.4%
-9385000
EPS (Basic)
$-2.44
-3.4%
$-2.36
+42.2%
$-4.08
-67.2%
$-2.44
+17.6%
$-2.96
EPS (Diluted)
$-2.44
-3.4%
$-2.36
+42.2%
$-4.08
-67.2%
$-2.44
+17.6%
$-2.96
Shares (Diluted)
3.2M
+0.1%
3.2M
+0.8%
3.2M
+0.0%
3.2M
+0.3%
3.2M
Passage Bio (PASG) โ€” Financials